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Implantable drug release platforms that offer wirelessly programmable control over pharmacokinetics have 
potential in advanced treatment protocols for hormone imbalances, malignant cancers, diabetic conditions, and 
others. We present a system with this type of functionality in which the constituent materials undergo com-
plete bioresorption to eliminate device load from the patient after completing the final stage of the release pro-
cess. Here, bioresorbable polyanhydride reservoirs store drugs in defined reservoirs without leakage until wirelessly 
triggered valve structures open to allow release. These valves operate through an electrochemical mechanism of 
geometrically accelerated corrosion induced by passage of electrical current from a wireless, bioresorbable 
power-harvesting unit. Evaluations in cell cultures demonstrate the efficacy of this technology for the treatment 
of cancerous tissues by release of the drug doxorubicin. Complete in vivo studies of platforms with multiple, inde-
pendently controlled release events in live-animal models illustrate capabilities for control of blood glucose levels 
by timed delivery of insulin.
INTRODUCTION
Implantable devices for drug delivery offer powerful capabilities 
in localized and controlled pharmacological treatments, where 
structural designs and/or material properties support the necessary 
functionality. Most of these platforms rely on passive drug diffu-
sion from porous scaffolds or on release from soft polymer matri-
ces that biodegrade over time (1–4). These devices operate on the 
basis of diffusion-controlled leakage of drug molecules, with rates 
that depend on the state of the system as it interacts with the sur-
rounding biology. Although technologies with electronically pro-
grammable valves built into reservoirs and fluidic channels enable 
much greater versatility in the controlled drug release kinetics (5–7), 
secondary surgical procedures to extract the implanted hardware 
after completion of the delivery function are required. To overcome 
these key disadvantages, drug delivery platforms should ideally in-
corporate (i) active systems with wireless control, (ii) mechanically 
stable reservoir structures with complete sealing for zero leakage 
of drugs in the off state and compatibility with any drug chemistry, 
and (iii) fully bioresorbable construction to eliminate the need for 
secondary surgical removal processes after treatment.
Recent reports describe active classes of bioresorbable elec-
tronic systems that store drugs in porous polymer molecular matri-
ces or chemically conjugated polymer structures, where wirelessly 
delivered thermal stimuli trigger the release processes (8–10). Tao et al. (8) 
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describe thermally accelerated drug release devices that use a silk-
based structure, but with rapid rates of degradation and disinte-
gration, often within timescales of minutes or hours. Lee et al. (9) 
report electronically programmable devices based on temperature- 
sensitive lipid-based structures. A disadvantage is that the lipid 
can collapse due to its weak molecular bonding, leading to unwanted 
leakage of drugs. Another approach (10) uses a wireless, thermal actu-
ation scheme to release physically trapped and covalently con-
jugated drug molecules from an oxidized starch–based structure. In 
particular, hydrophilic drug molecules remain within the materials 
structure, and heating (~42°C) accelerates diffusive release. Although 
these hyperthermic platforms (8–12) offer advantages over many 
other options, limitations follow from their sensitivity to uncon-
trolled variations in temperature over a narrow operating range, 
mechanical perturbations, and/or swelling of the polymer matrices 
during or after implantation. Moreover, these platforms are not 
drug release vehicles in the engineering sense of reservoirs, valves, 
channels, and other fluid handling systems. As a result, the pay-
loads and release kinetics are constrained by the degradable matrix 
and the nature of the molecular interactions that are responsible 
for binding.
Here, we introduce an approach that allows deterministic con-
trol over the delivery process in the form of a completely bioresorb-
able electronic system that combines biocompatible wireless 
power-harvesting function with electrochemically degradable valves 
and a system of reservoirs constructed from a bioresorbable poly-
mer. The result provides for programmable control over drug re-
lease in a platform that disappears completely and naturally in the 
body without residue. Specifically, wirelessly delivered electrical current 
initiated by proximity to a transmission coil leads to electrochemically 
accelerated dissolution of a metal gate structure that seals drug- 
containing reservoirs constructed in a bioresorbable polyanhydride. 
Unlike hyperthermic actuation (8–12), this crevice corrosion phe-
nomenon for opening of the gate enables fast and energy-efficient 
drug release. Exploiting this scheme using metal gates with various 
shapes and sizes allows the delivery of effective doses to target 
tissues with desired kinetics. As a result, this technology enables in 
situ, on-demand release of single or multiple classes of drugs from 
a collection of independently controlled reservoirs, with precise 
control of the release timing and near-zero parasitic leakage over 
extended periods of time. Systematic in vivo and in vitro studies 
demonstrate the underlying principles and all of the relevant fea-
tures of operation.
RESULTS AND DISCUSSIONS
Structure and operation of bioresorbable, wireless drug 
delivery device
Figure 1A highlights the design aspects and key materials for a simple 
system of this type, consisting of a polymer reservoir, a wireless power 
harvester, and a metal gate valve. Polybutanedithiol 1,3,5-triallyl- 
1,3,5-triazine-2,4,6(1H,3H,5H)-trione penteonic anhydride (PBTPA), 
a bioresorbable polyanhydride (13), serves as a substrate and a 
containment vessel for an aqueous drug of interest. Synthesis of 
the PBTPA relies on thiol-ene click reactions of three compounds ini-
tiated by exposure to ultraviolet (UV) light: 4-pentenoic anhydride 
(4PA), 1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (TTT), 
and 1,4-butanedithiol. The UV curing process facilitates the use of 
molding and/or machining techniques, to yield platforms of this 
type with a range of sizes and shapes, as indicated in fig. S1. The 
simple example shown here involves a single reservoir, with a pair 
of magnesium (Mg) electrodes assembled with the PBTPA housing. 
The wireless power harvester relies on magnetic inductive coupling 
to an external transmission coil to produce an electrical bias be-
tween the Mg electrodes, where one serves as an anode (referred to 
as the gate, which functions as the valve to an underlying reservoir) 
and the other as the cathode. This harvesting unit consists of a ra-
dio frequency (RF) coil of Mg, an RF diode constructed using a 
silicon nanomembrane (Si NM), and a parallel-plate capacitor in a 
multilayer stack of Mg/SiO2/Mg, as shown in Fig. 1A(i). The reso-
nance frequency is ~5 MHz, as shown in Fig. 1B, with scattering 
parameters, quality factor, and inductance values consistent with com-
putational modeling (note S1). Magnetic coupling at this frequency 
involves negligible parasitic absorption by biological tissues (14, 15). 
A relatively high Q ~ 15 (Fig. 1C) allows for long operating dis-
tances (~5 cm). A transmission coil (80-mm diameter, 3 turns, and 
winding with 1.6-mm diameter copper wire) added to the simulation 
model yields a relationship between the power transfer efficiency 
and operating distance, as shown in Fig. 1D (detailed information is 
in note S1).
The optimized power harvester generates an overpotential (bias), 
which leads to accelerated electrochemical etching with geometrical 
effects induced by the PBTPA housing. First, a bias develops be-
tween the anode gate and the cathode upon activation of an RF 
transmission coil placed in proximity to the device (14). This 
bias results in irreversible Faradaic reactions enabled by surround-
ing biofluids (15), according to the following anodic reaction: 
(Mg → Mg2+ + 2e−) (16). This reaction opens the gate and causes 
the release of drug from the underlying reservoir. Figure 1E demon-
strates wirelessly controlled release of water (4 ml, dyed blue) from a 
reservoir of a device immersed in a bath of phosphate-buffered 
saline (PBS; Sigma-Aldrich, USA) due to opening of the gate by 
electrochemical etching induced by passage of RF power (~12 mW 
into the receiver coil; 8 W into the transmission coil) through a 
transmission coil located at a distance of 2 cm outside of the bath. 
This process induces no notable heating (fig. S2). In this manner, the 
system supports the wirelessly controlled release of drugs, 
on- demand and with access to various amounts of drug solution 
(micro- to milliliter), as key advantages compared to conventional 
systemic delivery.
Dissolution studies of whole drug delivery system
A key defining characteristic of the system is that all of its constituent 
parts undergo complete dissolution into biocompatible end-products 
(17). Figure 1F illustrates the processes associated with accelerated 
dissolution of the entire system in a bath of PBS (pH 7.4) at 85°C for 
more than 4 weeks, including the PBTPA reservoir (100 m), the 
Mg (50 m, ~100 g) RF coil encapsulated by PBTPA (20 m), 
Si NM (320 nm) RF diode, and Mg/SiO2/Mg (30 m/100 nm/30 m) 
capacitor (fig. S3). The rate of dissolution of PBTPA can be adjusted 
through control of the molar ratios of 4PA, TTT, and 1,4-butanedithiol, 
which for cases explored here are 1:4:7 (referred to as PBTPA 1:4:7) 
and 1:1:2.5 (referred to as PBTPA 1:1:2.5) (13). The results of Fig. 1F 
use the latter formulation. Since the 4PA contains hydrophilic and 
degradable bonds and 1,4-butanedithiol provides hydrophobic chains, 
a high ratio of 1,4-butanedithiol in PBTPA (1:4:7) extends the time 
for dissolution. The corresponding time at body temperature can 
be estimated from results obtained at elevated temperatures and 
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associated Arrhenius scaling relationships to approximate the tem-
perature dependence (18)
  k PBTPA =  k 0 ‧ exp(− E A / RT) 
where k0 is the preexponential factor, EA is the activation energy, 
R is the universal gas constant (=8.314 J∙K−1 mol−1), and T is the 
absolute temperature. Measured rates of dissolution of the PBTPA 
(1:1:2.5) at different temperatures (0.5, 6.7, and 16.3 mg/day at 23°, 
60°, and 85°C, respectively), yield values of k0 and EA as 3.29 × 108 
and 51,500 J∙mol−1, respectively (fig. S4). As a result, the PBTPA 
reservoir (1:1:2.5, 450 mg, 100 m thick) has a projected lifetime of 
~660 days at 37°C in PBS (pH 7.4). The other individual components 
of the system dissolve more quickly than the reservoir, ~50 days for 
the Mg (50 m) coils (19), ~100 days for the Si NM (320 nm) diode 
(20), ~60 days for the Mg/SiO2/Mg (30 m/100 nm/30 m) capacitor 
(21), and ~30 days for the Mg (30 m) electrodes. The time for dis-
solution of the system can be reduced by decreasing the thickness of 
Fig. 1. Wirelessly programmable, bioresorbable drug delivery system. (A) Illustration and images of an implantable and wirelessly controlled bioresorbable drug 
delivery system with an electrical triggering unit that includes a radio frequency (RF) power harvester with a Mg coil, a silicon nanomembrane (Si NM) diode, and a 
Mg/SiO2/Mg capacitor, [A(i)]. (B) RF behavior (scattering parameter, S11) of the harvester (black, experiment; blue, simulation). The resonance frequency is ~5 MHz, selected 
to allow magnetic coupling with little parasitic absorption by biological tissues. (C) Simulated inductance (black) and Q factor (red) of a single coil with a diameter of 
16 mm. (D) Transmitting power as a function of the distance between the transmitting coil and the device (black, experiments; red, simulation). Experimental data are 
means ± SD; n = 3. (E) Images of wirelessly controlled release of a blue dye in water during immersion in phosphate-buffered solution (PBS; pH 7.4). (F) Accelerated dis-
solution of an entire system due to immersion in PBS (pH 7.4) at an elevated temperature, 85°C. Photo credit: Jahyun Koo, Korea University.
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the PBTPA or by adjusting the molar ratios of the reactant chemi-
cals, to values in the range of a few hundred days.
Opening mechanism by electrochemically triggered  
crevice corrosion
A critically important aspect of the release mechanism is that the 
confined geometry at the interface between the gate and PBTPA 
housing leads to accelerated rates of electrochemical etching, some-
times referred to as crevice corrosion (16, 22, 23), as shown in 
Fig. 2A. Figure 2B presents an illustration and a set of images of the 
system and the location of the gate defined by the housing. The 
insets of Fig. 2B show optical microscope (OM; left) and scanning 
electron microscope (SEM; right) images of the results of electro-
chemical etching with a bias of 1 V for 180 s. Images of the backside 
of the gate shown in Fig. 2C and fig. S5 illustrate that the highest 
etching rates occur at the vertices, followed by the edges. Electro-
chemical impedance spectroscopy (EIS) measurements performed 
at regular time points during the etching process yield insights into 
the gate morphology and the gate-electrolyte interface. Figure S6A 
shows a schematic illustration of the interfaces between the gate and 
biofluid and of a Randles’ equivalent circuit (24). Here, the solution 
resistance (Rs), the charge transfer resistance (Rct), and the constant 
phase element (CCFE) define the nature of the electrochemical pro-
cesses (fig. S6B). A factor “n” in equation ( jC = ( j)nCCPE) varies 
between a value of 1 and 0, with the higher extremity representing a 
pure capacitor while the lower characterizing a resistor. When n is 
between 0 and 1, its value provides information about diffusion 
phenomena, surface morphology, and other dissipative processes 
(25). After etching for 30 s, the value of n tends to decrease, likely 
due to increasing roughness and/or porosity on the surface of the 
electrode, as expected (26, 27) and as observed in SEM images 
(fig. S7). Although the initial electrode surface likely supports a thin 
oxide layer, electrochemical etching forms Mg(OH)2 according to 
Mg + 2H2O → Mg(OH)2 + H2. The combined effect of the oxide 
and hydroxide, which are both simultaneously forming and dissolv-
ing into the surrounding biofluids throughout the process (19, 28), 
leads to capacitive behavior between the electrolyte and electrode. 
As the etching proceeds, the thickness of the corrosion layer (d) 
increases, thereby decreasing the capacitance (C) according to 
C = 0S · d−1 (where 0, , and S are the vacuum permittivity, dielectric 
constant, and surface area of the electrode, respectively) (fig. S6) 
(29). After termination of electrochemical etching under applied bias, 
the residual Mg(OH)2 and oxides eventually disappear completely 
via dissolution at rates of several nanometers per day, depending on 
the details of the chemistry of the surrounding solution (19).
Quantitative characterization of the crevice corrosion phenomena 
is most easily conducted with molybdenum (Mo) gates (10 m 
thick), due to the comparatively smooth morphology of the thin 
oxide film (MoO3) and the reduced rates of dissolution compared 
to Mg. The central region, away from the perimeter, exhibits the 
slowest rates. A magnified OM image of the gate and an optical 
profilometry image at a vertex (Nexview, Zygo Corporation, USA) 
Fig. 2. Geometrically accelerated corrosion as the mechanism for opening a gate. (A) Design of an implantable and wirelessly controlled, bioresorbable drug delivery 
system. (B) Illustration and image of a Mg gate defined by an opening through a cover of PBTPA. The locations where the edges of this opening meet the underlying Mg 
create regions of crevice corrosion. The insets show optical microscope (OM; left) and scanning electron microscope (SEM; right) images of the electrochemically accelerated 
corrosion that occurs along these edge locations. (C) Back side view images of an electrochemically etched Mg gate (3 mm by 3 mm) at an applied potential of 1 V (~5 mA) 
for 0, 30, 90, and 180 s, respectively. (D) Nyquist plot: Z′, real part of impedance; Z′′, imaginary part of impedance. (E) OM image of the electrochemically accelerated corrosion 
of a Mo gate (3 mm by 3 mm, 10 m thick) at an applied voltage of 5 V (~6 mA) for 60 s. (F) Three-dimensional (3D) topography image and surface profile measurement 
of the corroded Mo gate near the edge of the PBTPA (1:1:2.5) opening, obtained using a 3D optical profiler (Nexview, Zygo Corporation, USA). Photo credit: Ji-Hyeon Park, 
Northwestern University.
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in Fig. 2 (E and F) confirm the differential rates of corrosion ki-
netics across different regions. The relative depth of the corrosion 
along the white arrow with the broken line (between A and B) in 
Fig. 2F indicates that the corrosion rates at the edges and vertex 
regions are ~10 times higher than that at the central region, i.e., 
~5.6 × 10−8 and ~4.1 × 10−9 mg‧mm2‧s−1, respectively. These rates 
follow from estimates of the areas for uniform (~280 mm2) and 
crevice (~26 mm2) corrosion determined from the OM image 
(1 V for 200 s) and from the etched Mo volume extracted from the 
three-dimensional topology data (fig. S8A). These observations are 
consistent with crevice corrosion processes that arise at dissimilar 
junctions (16, 22, 23) due to reduced rates of mass transfer at the 
edges and associated enhancements in anodic effects. Figure S8B 
presents sequential images of the structure at 10, 20, and 30 s of 
electrochemical etching with a bias of 5 V. The images illustrate that 
the crevice corrosion at the perimeter of the anode dictates the 
opening of the gate and associated release. As a result, only a rela-
tively small amount of the gate (i.e., along the perimeter) must 
be etched away to produce an opening event, thereby allowing for 
the rapid release of drugs upon a trigger event.
Trigger and release behaviors of bioresorbable drug 
delivery device
Figure 3 (A to D) summarizes the effect of applied voltage, gate area, 
and thickness on the time required to open the gate (t0), as deter-
mined using an electrochemical analyzer (Short VMP3, Bio-Logic 
Science Instruments, USA). Figure 3A shows the corrosion current 
as a function of time for gates with fixed dimensions (thickness, 30 m; 
area, 3 mm2 by 3 mm2) at various applied voltages. The crevice 
corrosion leads to electrical isolation and opening, as defined by a 
sudden decrease in the corrosion current to a value close to zero 
(Fig. 3A). Analysis of these data defines the relationship between 
applied voltage, time (t0) required to open (fig. S9A), and corrosion 
rate (fig. S9B). Both the amount of etched metal and the corrosion 
rate follow Faraday’s law (eqs. S6 to S8 in note S3). As expected, t0 
and the corrosion rate are proportional to the applied voltage. Fig-
ure 3B reveals a direct relationship between the gate area and t0 for 
a fixed voltage (0.5 V) and gate thickness (30 m). Additional ex-
periments involve studies of Mg gates with similar surface areas but 
different perimeters: circular (radius, r = 3 mm) and cross (length of 
a side, a = 2.38 mm) shapes (fig. S10A). The former (perimeter, 
18.84 mm; area, 28.26 mm2) and latter (perimeter, 28.56 mm; 
area, 28.32 mm2) exhibit t0 values (n = 4, mean) of ~202 ± 65 
and ~270 ± 41 s, respectively, as shown in fig. S10 (B and C). The 35% 
smaller perimeter of the circular shape compared to the cross leads 
to a ~35% shorter value for t0, indicating that the length of perimeter 
defines t0 rather than surface area, as expected due to the crevice 
corrosion mechanism. The gate thickness also influences t0, as the 
corrosion process must propagate through the thickness to induce 
an opening (Fig. 3C).
The selection of gate material is also important. A comparison of 
t0 for Mo and Mg gates illustrates this point (Fig. 3D). The higher 
nobility of Mo compared to Mg reduces its corrosion rate, thereby 
increasing t0. Linear sweep voltammetry (LSV) offers a simple route 
to visualize and compare the corrosion properties of different metals. 
Figure S11 shows representative LSV polarization curves for Mg 
and Mo. The anodic dissolution of Mg begins ~−0.77 V, while Mo 
begins at ~−0.44 V (with respect to Ag/AgCl reference electrode). 
Fig. 3. Trigger and release behaviors of bioresorbable drug delivery vehicles with electrochemical control. (A) Dependence of the trigger time on applied potential 
at fixed Mg gate size (30 m thickness, 3 mm by 3 mm area). (B) Effect of the exposed area of the gate on trigger time at a fixed applied potential (0.5 V) and gate thickness 
(30 m). (C) Dependence of trigger time on thickness of the gate, for a fixed applied potential (0.5 V) and gate area (3 mm by 3 mm). (D) Comparison of the trigger time of 
Mg (30 m at 0.2, 0.5, and 1 V) and Mo (10 m at 1 V) gates for various perimeters of the gates. (E) Kinetics of the release of doxorubicin after triggering to open an area of 
2 mm by 2 mm in the Mg gates. (F) Leakage of drug (doxorubicin) through the layers of material used for the reservoir and the gates [black, Mg (50 m thick); red, Mo 
(10 m thick); and blue, PBTPA 1:4:7 (100 m thick)] during immersion in PBS at body temperature (37°C). Photo credit: Jahyun Koo, Korea University.
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At any applied voltage, for otherwise similar conditions, the Mg 
corrodes at a higher rate than Mo, thereby reducing t0. On the basis 
of these results, devices with Mg gates are best suited for rapid drug 
release over short times, considering the relatively fast rates of nat-
ural dissolution of Mg in biofluids (~1 m/day at 23°C) (19). Mo 
gates are applicable to systems that demand long-term dosing and 
survivability, considering the comparatively slow rates of dissolution 
(0.2 to 0.5 nm/day at 23°C) (19).
Demonstrations and studies of cumulative drug release rely on 
doxorubicin (0.2 mg diluted in 0.2 ml of PBS) in a wired device built 
using a reservoir constructed in PBTPA (1:4:7). Immersing such 
a device in 3 ml of PBS in a cuvette and electrochemically opening 
the gate enable time-dependent analysis of release via optical [UV- 
visible (UV-vis)] spectroscopic measurements of an absorption 
peak ( = 485 nm) associated with the doxorubicin (30). Data col-
lected in this manner define the kinetics of the diffusion-controlled 
release processes. Figure 3E shows the cumulative release of doxo-
rubicin from a device with an Mg gate (2 mm by 2 mm, 30 m thick) 
after applying a trigger at 1 V for 5 min. The increase in absorbance 
at 485 nm corresponds to gradual release of the drug into the 
surrounding PBS (fig. S12) (30). The data indicate that ~70% of the 
doxorubicin releases within 10 min after triggering. Figure 3F 
shows that the leakage of drugs from a completed system [black, Mg 
(50 m thick); red, Mo (10 m thick); blue, PBTPA 1:4:7 (100 m 
thick)] before opening of the gate is negligible during immersion in 
PBS at body temperature (37°C) for more than 30 days (fig. S13).
As mentioned in the context of the results of Fig. 1F, processes of 
dissolution and bioresorption of the PBTPA reservoir determine 
the overall lifetime of the drug delivery platform. The functional 
lifetime (tf), as defined by the maximum time that the drugs can 
be stored in the system without leakage, depends on the rate of dis-
solution of the metal gate (i.e., Mg gate; ~30 days, 30 m thick) in 
the absence of a triggering event. This time, then, can be written as
  t f =  h 0 ‧  k −1 
where h0 is an initial thickness of gate, and k is its rate of dissolution 
in biofluids. The time required for the triggered release can there-
fore be expressed, for a given voltage, as
  t 0 =  ‧ ( h 0 –k ‧ t ) ‧  P m , (t ≤  t f ) 
where  is a factor that depends on the corrosion chemistry and the 
voltage, t is the time of immersion in biofluid before the initiation of 
a trigger event, and Pm is the perimeter of gate. Here, t0 is linearly 
proportional to the thickness of the gate (h0 − k‧t) that remains at 
the time of triggering. For example, the functional lifetime of 30-m 
Mg (tf,Mg) is about 30 days, considering the natural rate of Mg dis-
solution (kMg = ~1 m/day) (19). In the case of Mo, the functional 
lifetime (tf,Mo) is ~103 times longer than Mg at the same thickness 
(19), while the trigger time of Mo (t0, Mo) is only ~10 times longer 
than Mg, according to Fig. 3D. The systems can be engineered over 
a wide range, to satisfy particular requirements.
In vitro cell demonstration of bioresorbable drug 
delivery device
Demonstrations of practical utility in oncology applications use a 
confluent culture of cells (NIH-3T3, HeLa, HepG2, and MDA-
MB-231). Figure 4 (A to C) presents a series of optical and fluores-
cence images with phalloidin staining of cell F-actin (green color) 
and 4′,6-diamidino-2-phenylindole (DAPI) staining of the cell 
nucleus (blue color) before and after a trigger event. Figure 4A shows 
the initial cell configuration at the start of the test as a reference; the 
inset highlights the test platform. Figure 4B demonstrates the non-
cytotoxicity of a device that contains doxorubicin (0.2 mg; Sigma- 
Aldrich, USA) immersed in Dulbecco’s modified Eagle’s medium 
(DMEM) (10 ml; Sigma-Aldrich, USA) for 1 hour. Here, Fig. 4B(iii) 
shows DAPI-stained NIH-3T3 nuclei (blue color indicated by white 
arrows) and actin [green color in Fig. 4B(ii)], consistent with un-
hindered cell attachment and spreading, without any evidence of 
cytotoxicity. Figure 4C(iii) shows that the DAPI-stained NIH-3T3 
nuclei significantly decrease upon RF triggered release of doxorubicin. 
The presence of DAPI staining outside of the nuclei and the de-
crease in the signals associated with DAPI-stained cells are both 
consistent with disruption and apoptosis induced by the doxorubicin 
(31), ~70% of which releases from the reservoir within 10 min of the 
gate-opening event (Fig. 3E). Figure 4D shows the relative number 
of alive NIH-3T3 cells determined by a cell counting kit-8 (CCK-8) 
as a function of time. During the initial stage (0 hours) and incuba-
tion (1 hour), the cell viability remains constant. Triggering at 1 hour 
after the start of the test results in a marked increase in the rate of 
cell death, as shown in Fig. 4D. Specifically, release of doxorubicin 
through the 3 mm by 3 mm gate decreases the cell population by 
half during a 1-hour period that includes 5 min of RF triggering, 
decreasing the area of cell adhesion (i.e., cell spreading) significantly. 
In addition, various tumor cells (HeLa, HepG2, and MDA-MB-231) 
provide similar results (Fig. 4, E to G). The viability of HeLa, HepG2, 
and MDA-MB-231 cells for 5 hours after triggering and release of 
doxorubicin are 16, 39, and 35%, respectively. The DAPI-stained 
tumor cells significantly decrease, consistent with an increased rate 
of death of tumor cells, with negligible prior changes in viability 
(Fig. 4, E to G, and fig. S14), as expected due to negligible rates of pas-
sive leakage of drugs.
In vivo operation of a multiple release, bioresorbable drug 
delivery device
Extension of this basic system to include multiple drug reservoirs 
and corresponding RF harvesters tuned to different resonance fre-
quencies allows for timed triggering of multiple release events, on 
demand. This type of multiple reservoir system can be used with a 
single drug or multiple combinations of them. Figure 5A presents a 
schematic illustration of a device that includes three independently 
addressable reservoirs and three harvesters (same outer diameter, 
12 mm; 16, 13, and 8 turns for the black, red, and blue coils, respec-
tively; see fig. S15 for the detailed geometrical layout). Separate con-
trol follows from distinct operating/resonance frequencies for each 
harvester. In this example, the three coils use matching capacitors of 
19, 23, and 85 pF, respectively, to achieve operating frequencies of 
5.14, 9.92, and 14.78 MHz. The values of Q for these coils are 9, 15, 
and 15, with corresponding bandwidths of 0.6, 0.7, and 0.9 MHz, 
respectively (fig. S16). The different resonance frequencies, taken 
together with the physical separation of the coils, minimize mutual 
interference (detailed information is in note S1). RF power applied 
to a transmitting coil (diameter, 80 mm; 3 turns) placed on top of 
the system yields different voltages across each harvester. The in-
duced voltage at the operating frequency of any one of the three 
harvesters is significantly larger (~10 times) than that of the other 
two (Fig. 5, B and C), as necessary for independent control and 
operation.
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Figure 5D shows an optical image of such a device, including 
three independent reservoirs and three harvesters. In vivo demon-
strations involve systems of this type filled with insulin and implanted 
under the skin of male Lewis rats (Fig. 5E). RF power delivered at 
different frequencies (5, 10, and 15 MHz) and different times inde-
pendently triggers each reservoir. For each case, more than 80% of 
the insulin releases into the surroundings within 10 to 30 min for 
gates with sizes of 3 mm by 3 mm, as shown in fig. S17. The insulin 
causes the liver to increase the conversion of glucose into glycogen 
and thereby reduce the glucose levels in the blood (32). A commercial 
meter (GLUCOCARD Vital, Arkray Inc., Minneapolis, USA) yields 
information on blood glucose concentration after the insulin re-
lease events (insulin solution human, Sigma-Aldrich, USA; 0.9 IU, 
defined as the “biological equivalent” of 34.7 g of pure crystalline 
Fig. 4. In vitro evaluation of NIH-3T3 cell and tumor cell (HeLa, HepG2, and MDA-MB-231) viability after triggered release of drug (doxorubicin). (A to C) Series 
of optical and fluorescence images of NIH-3T3 cells with phalloidin staining of cell F-actin (green; ii) and DAPI staining of the nuclei (blue; iii) before and after triggered 
release. The inset shows an image of a test platform used to study cell viability. (A and B) Images of the initial cell configuration and after 1-hour incubation with a device 
immersed in Dulbecco’s modified Eagle’s medium (DMEM) before triggering, respectively. (C) Images after triggering and release of doxorubicin from the device. Relative 
viability of (D) NIH-3T3, (E) HeLa, (F) HepG2, and (G) MDA-MB-231 cells before and after triggering (release point, 1 hour). Data are means ± SD; n = 3 per group. Statis-
tica software (Version 6.0) was used for statistical analysis followed by a t test. *P < 0.05 compared to any other group. Photo credit: Hojun Kim, University of Illinois at 
Urbana-Champaign.
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insulin per 1 IU). Triggered release of insulin from the implanted 
system has the expected effect. Triggering the first reservoir using 
an RF frequency of 5 MHz leads to the release of the first amount of 
insulin (0.9 IU diluted in 0.2 ml of PBS), as shown in Fig. 5F. An 
hour after releasing insulin and monitoring the glucose level, injec-
tion of glucose solution (3 ml; 50% dextrose injection, USP, Hospira 
Inc., USA) under the skin (subcutaneous tissue of the back of the 
animal) returns the glucose level to its initial value (over 90 mg/dl) 
within 30 min. After a 30-min recovery period, triggering the sec-
ond reservoir (using RF at 10 MHz) releases another dose of insulin 
(0.9 IU diluted in 0.2 ml of PBS). Another hour after monitoring, 
injection of glucose returns the level to its initial value again. Trigger-
ing the third reservoir (using RF at 15 MHz) repeats the process, 
thereby demonstrating the reliable operation of this type of wirelessly 
programmed and multiple drug release platform. This implantable 
system might be valuable for long-term usages with multiple days’ 
release of insulin when patients cannot perform injections them-
selves and they do not have access to health professionals.
In another example, integration of polymer structures near and 
around the gates allows for directional and localized release of lido-
caine for local pain block on the sciatic nerve. Figure 6A illustrates 
the three independent reservoirs of this platform and its nerve cuff 
for localized pharmacological delivery to the site of interest. The 
inset of Fig. 6A highlights the interface between the triple reservoirs 
and the poly(lactic-co-glycolic acid) (PLGA) cuff (4 mm by 8 mm, 
~20 m thick) that wraps the sciatic nerve to localize the release. A 
schematic illustration and image of the device and associated surgical 
procedures for implantation near the right sciatic nerve of a male 
Lewis rat appear in Fig. 6 (B to D). RF power delivered at different 
frequencies (5, 10, and 15 MHz) and different times independently 
triggers each reservoir. For each case, more than 80% of the lido-
caine releases along the PLGA cuff within 30 min for gates with 
Fig. 5. In vivo operation of a wirelessly programmable, bioresorbable drug release vehicle with three separately addressable drug reservoirs for regulation of 
blood glucose. (A) Illustration of a system with three separate reservoirs and wireless stimulator units. (B) Simulated and (C) experimentally measured (data are 
means ± SD; n = 3 per group) voltages of the three separate harvesters at different operating frequencies, to demonstrate minimal cross-talk. (D and E) Images of a device 
and surgical procedures for implantation in the subdermal area of the back of a rat model. (F) Changes in blood glucose level induced by wirelessly triggering the release 
of insulin sequentially from the three reservoirs. RF with different frequencies (5, 10, and 15 MHz) triggered each reservoir. After each release event and a subsequent hour 
of monitoring, glucose was injected under the skin to return the glucose level to its initial value within 30 min. Photo credit: Jahyun Koo, Korea University.
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sizes of 2 mm by 2 mm, as shown in Fig. 3E. The lidocaine preferen-
tially binds to the inactivated state of the voltage-gated sodium 
channels that conduct electrical impulses and mediate fast depolar-
ization along nerves to eliminate pain (33, 34). Maximum electro-
myograms (EMGs) obtained from the tibialis anterior (TA) muscle 
in uninjured rats confirm the ability to block the sensitivity of the 
sciatic nerve by programmed release of lidocaine (0.2%, ~20 l), as 
shown in Fig. 6E. The maximum EMG drops rapidly after RF trig-
gering and release. Figure 6F presents representative EMG data col-
lected in intervals of 15 min after triggered release events (0.2%, 
~20 l) in series (black, baseline; red, after the first trigger; blue, 
after the second trigger; and purple, after the third trigger). The 
muscle responses decrease after each release. In this manner, biore-
sorbable, localized release platforms of this type may offer potential 
utility in programmed, on-demand pain relief during and after re-
covery from an injury or a surgical operation.
The materials and strategies for fabrication support wide- 
ranging choices in sizes and geometries for the devices, including 
the use of miniaturized reservoirs for small-animal model studies. 
Figure S18A illustrates in vivo operation of a device with a single 
reservoir (5 mm by 5 mm by 2 mm) and a nerve cuff (2 mm by 
8 mm, ~20 m thick) for localized, pharmacological delivery to the 
sciatic nerve of a mouse. Here, the reservoir can be designed with 
dimensions across a wide range, down to a few hundred microns, to 
align with the minimum effective dose levels (i.e., micro- to milliliter). 
Figure S18B shows the procedures for implantation of a platform 
Fig. 6. In vivo demonstration of a wirelessly programmable, bioresorbable drug release vehicle with three independent reservoirs and a cuff structure as a local 
anesthetic for mitigation of pain. (A) Illustration of a system with triple reservoirs and a cuff structure as an interface to the sciatic nerve of a rat model. The inset high-
lights the design details and the nerve interface. (B and C) Schematic illustration and image of the device. (D) Images at various stages of implantation of the device and 
integration of its flexible poly(lactic-co-glycolic acid) (PLGA) cuff (4 mm by 8 mm, ~20 m thick) with the sciatic nerve to hold the position of the reservoir and to localize 
the release to the nerve. (E) Changes in the maximum EMG signal associated with wirelessly triggered released of lidocaine from each of the three reservoirs in series. 
Here, RF with different frequencies (5, 10, and 15 MHz) triggered each reservoir. After each release event of lidocaine (0.2%, ~20 l), the maximum EMG was recorded from 
the tibialis anterior (TA) muscle (data are means ± SD; n = 2). (F) Representative electromyogram (EMG) data for every 15 min after the trigger events and corresponding 
release of lidocaine (0.2%, ~20 l) in series (black, baseline; red, 15 min after the first trigger; blue, 15 min after the second trigger; and purple, 15 min after the third trigger). 
Photo credit: Jahyun Koo, Korea University.
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with a flexible PLGA (2 mm by 8 mm, ~20 m thick) nerve cuff that 
wraps sciatic nerve to hold the position of the reservoir and guide 
the release direction of lidocaine (1%, ~20  l) by RF triggering 
with 5 MHz for 5 min. Figure S18C shows an optical image of the 
sciatic nerve and adjacent muscle tissue for the case of the release of 
a blue dye solution. After the release of lidocaine (1%, ~20 l), the 
compound muscle action potential (CMAP; black) and sensory 
nerve action potential (SNAP; red) show expected changes over 2 
hours (data are means ± SD; n = 3), as shown in fig. S18D. Com-
plete blockage of activity of sciatic nerve occurs within 15 min 
after release and activity gradually recovers over the next ~2 hours, 
as illustrated (fig. S18E) by the decrease in CMAP (left) and SNAP 
(right) signals (red) relative to those before the trigger event (black). 
Specifically, the lidocaine blocks ~90% of CMAP and  ~94% of 
SNAP during the initial period after release. This miniaturized sys-
tem can also support multiple reservoirs with different types of 
drugs for cocktail therapy in oncology applications and/or long-
term release of drug for chronic treatment.
In vivo biocompatibility studies of bioresorbable device
Although the experiments described above reveal no signs of in-
flammation or immune reactions, separate evaluations of bio-
compatibility are useful. Tests for this purpose involve subdermal 
implantation of Mg (group I) and Mo (group II) devices, each of 
which includes an encapsulation layer of PBTPA (1:4:7, ~100 m 
thick), a gate (3 mm by 3 mm) and counter electrode (Mg, 50 m 
thick; Mo, 10 m thick), and a PBTPA (1:4:7) reservoir (1 mm by 
1 cm, ~900 m thick), in three groups of animals. A block of high- 
density polyethylene (HDPE; U.S. Food and Drug Administration–
approved nontoxic material), with 1-mm thickness and 1 cm by 
1 cm lateral dimensions similar to those of the test devices, serves as 
a control (group III). Here, electrochemical triggering uses a wired 
connection at 1 V for 5 min, performed shortly after subdermal im-
plantation. The devices remain implanted for 5 weeks after removal 
of the wired connection. Hematoxylin and eosin images of stained 
tissue sections collected after this period appear in Fig. 7 (A and B) 
and figs. S19 and S20. The metal components undergo dissolution 
and bioresorption within this time. Some minimal inflammatory 
response and fibrosis appear in close proximity to the implants, but 
no significant evidence of injury or damage occurs at the adjacent 
tissue and muscle layers. Additional evaluations involve careful 
examination of each hematoxylin and eosin slide for the presence of 
acute and chronic inflammation, granulation tissue formation, and 
fibrosis. OM images [high-power field (HPF; 40× objective] at the 
highest density of inflammation yield counts of neutrophils, lym-
phocytes, and giant cells (Fig. 7C). Presence or absence of granulation 
Fig. 7. In vivo biocompatibility studies. Hematoxylin and eosin images of stained tissue sections at 5 weeks after implantation of (A) devices and (B) samples of 
HDPE. Middle and right images show adjacent muscle fascia and muscle tissue, respectively. (C) Evaluations of histological scoring for reference controls (HDPE) and test 
groups (Mg metal gate and Mo metal gate devices) (n = 3 per group). PMN, polymorphonuclear. Boxplots show the median (center line), the third and first quartiles (upper 
and lower edge of box, respectively), and the largest and smallest value that is ≤1.5 times the interquartile range (limits of upper and lower whiskers, respectively). Photo 
credit: Matthew MacEwan, Washington University in St. Louis.
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tissue can be scored as absent, focal, or diffuse. Fibrosis scores 
on the Masson stain use were as follows: none = 0, mild = 1, moder-
ate = 2, and severe = 3, as in Fig. 7. Measurements of weight change 
at 5 weeks after implantation show no significant differences (fig. 
S21). Counts of white blood cells in peripheral blood serum by 
cytometric bead arrays also indicate no significant differences be-
tween groups (fig. S22). These results, together with previously 
reported findings, provide strong evidence of the biocompatibility 
of the individual constituent materials used in the platforms pre-
sented here, such as PLGA (35), Mg (36), Mo (37), Si NM (20) and 
their use in other types of devices (14).
In summary, wirelessly programmable, battery-free drug delivery 
systems constructed entirely of bioresorbable materials represent a 
versatile class of technology for targeted pharmacologic treatment 
across a range of applications. The efficient containment and the en-
gineered reservoir approach facilitate application to broad classes of 
pharmaceuticals, including proteins and hormones. Additional op-
portunities are in cocktail therapies and controlled pharmacokinetics 
enabled by multiple, independently controlled reservoirs. The de-
velopment of advanced approaches based on chip-based microcon-
trollers to scale the number of reservoirs significantly beyond those 
of the systems presented here represents a direction for future work. 
These schemes enable long-term delivery and precise dosing if im-
plemented with reservoirs that have individual volumes below a 
therapeutic concentration.
MATERIALS AND METHODS
Preparation of wireless, bioresorbable drug release vehicles
Preparation of the materials began with mixing of 4-PA, TTT, and 
1,4-butanedithiol with a molar ratio of 1:4:7 (PBTPA 1:4:7) or 
1:1:2.5 (PBTPA 1:1:2.5) in polydimethylsiloxane (PDMS) molds. 
Initiating a thiol-ene click reaction by adding photoinitiator (5 weight %) 
and exposing to UV light ( = 365 nm) formed PBTPA for the bio-
resorbable reservoirs (13). Wet etching of foils (Mg foil, 10 to 50 m 
thick; or Mo foil, 10 m thick) yielded bioresorbable metal electrodes. 
An uncured layer of PBTPA bonded a film of PBTPA (50 m thick) 
with holes defined by a laser cutting process onto the metal elec-
trodes. Exposure to UV light (4 W,  = 365 nm) for 10 min com-
pletely cured the entire structure. The extended metal electrodes 
were connected to a wireless stimulator unit built using a RF receiv-
er coil of Mg, an RF diode constructed using a Si NM, and a parallel- 
plate capacitor in a multilayer stack of Mg/SiO2/Mg. Biodegradable 
conductive paste (Candelilla wax/W powder) electrically connected 
the individual components (14).
Measurements of permeability of drugs through  
constituent materials
A 1-cm-thick slab of PDMS (Sylgard 184, Dow Corning, USA) cast 
in a well structure served as a test vehicle for assessing permeation 
of aqueous solutions of drugs through layers of materials used in the 
devices (fig. S11). Mg (50 m thick), Mo (10 m thick), or PBTPA 
(1:4:7, 100 m) served as seals on the top of the PDMS well, bonded 
using an epoxy (LOCTITE EPOXY, Henkel Corp., USA). A syringe 
injection process delivered a drug solution (1 ml) through the side 
wall of the well. Sealing this injection location with epoxy prevented 
leakage. A coating of epoxy covered the entire system, including the 
side and back wall surfaces of the PDMS, to securely bond the 
test film in a vial filled with PBS (10 ml) and held at body tempera-
ture (37°C) for 30 days. At regular time intervals, samples of PBS 
(3 ml) collected from the vial were transferred to a cuvette for 
UV-vis spectroscopy. An absorption peak at 485 nm in the UV-vis 
spectrograms (UV-2450, Shimadzu Corp., Japan) allowed deter-
mination of the concentration of doxorubicin, as described previ-
ously (30). After each measurement, the PBS was returned to the 
original vial.
In vitro demonstration and evaluation of cell (NIH-3T3, 
MDA-MB-231, HepG2, and HeLa) viability
NIH-3T3 fibroblasts were cultured in DMEM (Gibco-BRL, USA) 
supplemented with 10% (v/v) fetal bovine serum (Gibco-BRL) and 
penicillin-streptomycin (100 U/ml; Gibco-BRL). The relative num-
bers of live cells were determined using a CCK-8 according to the 
manufacturer’s protocol (n = 3 per group). MDA-MB-231, NIH-3T3, 
and HepG2 cells treated with the device, electrical trigger, and/or 
doxorubicin were imaged using an OM. The cells were fixed, per-
meabilized, and subsequently incubated with Alexa Fluor 488–
phalloidin (Molecular Probes) and DAPI (Sigma-Aldrich) to stain 
cell actin and nucleus, respectively. Imaging used a laser scanning 
confocal microscope (LSM 710, Zeiss). Phalloidin staining of cell 
actins enabled examination of the effects on cell adhesion.
EIS measurements of corrosion processes
Gates of Mg and Mo with circular shapes (radii of 1, 1.2, 1.4, 1.6, and 
1.8 mm) defined by PBTPA (1:4:7) were submerged in an electro-
chemical cell at room temperature with PBS as the electrolyte and 
with a counter electrode of Cu and a reference electrode of Ag/
AgCl. The corrosion followed from application of potentials at 0.5 
to 5 V for 0.5 to 5 min using a potentiostat (Metrohm Autolab B.V., 
The Netherlands). The polarization measurements involved a scan 
rate of 1 mV/s and a scanning range from −1 to 1 V.
Electromagnetic simulation
Finite-element analysis yielded the scattering parameters (S11), the 
inductance (L), and the Q factor (Q) of the Mg RF coil with a match-
ing capacitor. The simulations (Ansys HFSS 13 User’s Guide, Ansys 
Inc., 2011) used a lumped port to define the S11 and the port 
impendence (Z). An adaptive mesh (tetrahedron elements) ensured 
computational accuracy, to yield L = ZIm/(2f) and Q = |ZIm/ZRe|, 
where ZRe, ZIm, and f represent the real and imaginary parts of Z and 
the frequency, respectively. A transmission coil (80 mm diameter, 
3 turns, and winding with 1.6-mm diameter copper wire) added to 
the simulation model yielded a relationship between the power trans-
fer efficiency and operating voltage.
In vivo demonstration of wirelessly triggered lidocaine 
release for sciatic nerve block
Male mice (30 g; C57BL/6J, the Jackson laboratory, USA) were 
anesthetized using isoflurane gas (3% for induction and 2% for 
maintenance) during surgical implantation of a bioresorbable drug 
delivery reservoir onto the right sciatic nerve of the animal. After 
the implantation, the surgical wound was closed with 8-0 Vicryl 
sutures and Autoclip wound clips (12020-09, Fine Science Tools). A 
signal generator (3390, Keithley, USA) and a high-frequency amplifier 
(8447E, Agilent, USA) provided RF power to a transmitter coil 
(80 mm diameter, 3 turns) placed over the implantation site to wirelessly 
power the implanted drug delivery device. After triggering the Mg 
metal gate for 5 min and release of lidocaine (Xylocaine-MPF 1%, 
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Fresenius USA), CMAP (black) and SNAP (red) were measured (data 
are means ± SD; n = 3) with 1″ length, 0.30-mm diameter concen-
tric needle electrodes (S53153 TECA, USA) on a VikingQuest EMG 
system using Synergy master software (982A0386, Natus, USA).
In vitro insulin release
Here, devices with insulin solution (0.9 IU diluted in 0.2 ml of PBS) 
and various metal gate sizes (1 mm by 1 mm to 5 mm by 5 mm) 
were triggered in a 25-ml vial filled with 10 ml of PBS solution. 
Small volumes (3 ml) of solution collected from different devices 
and vials for each time point were transferred in an insulating 
box (~2°C, within 24 hours) to the Diabetes Research Center at 
Washington University in St. Louis for measurements of the con-
centration of insulin.
In vivo demonstration of wirelessly triggered insulin release 
from systems with multiple reservoirs
Male Lewis rats (300 g; Charles River Laboratories) were anesthetized 
using isoflurane gas (4% for induction and 2% for maintenance) 
during surgical implantation of a bioresorbable drug delivery reser-
voir into a subcutaneous pocket in the back area of the animal. After 
implantation, the surgical wound was closed with 4-0 nylon sutures. 
A signal generator (3390, Keithley, USA) and a high- frequency 
amplifier (8447E, Agilent, USA) provided RF power to a transmit-
ter coil (80 mm diameter, 3 turns) placed over the implantation site 
to wirelessly power the implanted drug delivery device. After trig-
gering the metal gate, blood glucose level monitoring was per-
formed each hour over a time of 5 hours. A 23-gauge needle was 
used to prick the tip of the toe for blood sampling.
In vivo biocompatibility tests
Two types of devices [Mg gate device (group I, n = 3) and Mo gate 
device (group II, n = 3)] and a control group (group III, n = 3) were 
implanted in male Lewis rats (n = 9). All animal studies were 
performed in accordance with Institutional Animal Care and Use 
Committee at the Washington University in St. Louis. Male Lewis 
rats (300 g; Charles River Laboratories) were anesthetized using 4% 
isoflurane/96% oxygen (induction) and 2% isoflurane/98% oxygen 
(maintenance) administered by inhalation. Before implantation, 
test devices (Mg gate and Mo gate) and reference materials (HDPE) 
were sterilized by exposure to ethylene oxide. The devices were im-
planted into a pocket created beneath the skin on the backs of the 
animals. Electrical triggering involved a wired connection at 1 V for 
5 min to open the gates. After the triggering event, the device was 
implanted for 5 weeks with the wired connection removed. At 
the terminal time point, the animals were weighed (fig. S21), and 
venous blood was collected from the tail vein to assess for complete 
blood count and systemic toxicity (fig. S22). For histological analysis, 
the skin tissue and subcutaneous pockets containing the materials 
were excised and fixed in 10% neutral-buffered formalin, embedded 
in paraffin, and stained with hematoxylin and eosin.
Hematoxylin and eosin staining
Fixed skin samples were placed in a Tissue-Tek VIP 1000 tissue 
processor where they were submerged in graded alcohols followed 
by xylene and infiltration with paraffin. An embedding process 
formed paraffin blocks that were then sectioned on a Leica RM2125 
RTS rotary microtome. The slides were deparaffinized and hydrated 
through graded alcohols. Staining used exposure to a modified Harris 
hematoxylin (Richard-Allen Scientific, Kalamazoo, Michigan) for 
2 min followed by differentiation in 0.1% acid alcohol and bluing in 
0.1% ammonia water. After two rinses in 95% ethyl alcohol, samples 
were placed in an eosin Y with phloxine (Richard-Allen Scientific, 
Kalamazoo, Michigan) for 30 s. The samples were then dehydrated, 
cleared, and mounted.
Toluidine blue staining
The slides were deparaffinized and hydrated through graded alco-
hols to water. The slides were then placed in 0.1% aqueous toluidine 
blue O (Allied Chemical, Rochester, NY) solution for 10 min. After 
rinsing in tap water, the samples were dehydrated quickly through 
95 and 100% ethyl alcohol. This step was closely monitored to yield 
the correct amount of differentiation. The slides were then cleaned 
in xylene and mounted.
Histological scoring
A pathologist (M.P.) performed the histologic evaluation of the 
tissue at the Northwestern University, Feinberg School of Medicine. 
Each hematoxylin and eosin slide was carefully reviewed for the 
presence of acute and chronic inflammation, granulation tissue 
formation, and fibrosis. Neutrophils, lymphocytes, and giant cells 
were counted in a representative HPF (40× objective) with the highest 
density of inflammation. Presence or absence of granulation tissue 
was scored as absent, focal, or diffuse. Fibrosis was scored on a Masson 
stain as none = 0, mild = 1, moderate = 2, and severe = 3.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/35/eabb1093/DC1
View/request a protocol for this paper from Bio-protocol.
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